STING Agonist Combinations for Checkpoint-Resistant Cancer

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for new cancer treatment regimens that provide a beneficial effect in prolonging patient's lives while maintaining a high quality of life, especially for cancers resistant or refractory to current therapeutic regimens, including combinations of therapeutic agents that can potentially decrease the rate of relapse.

Innovation Solution

Administering a STING agonist, such as Compound No. 14, in combination with checkpoint inhibitors like anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies, to treat various cancers, including solid tumors and hematological malignancies.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional cancer treatments (surgery, radiotherapy, cytotoxic chemotherapies) are used, then cancer can be treated, but treatment efficacy is limited and cancer survival rates need improvement

Engineering Contradiction:

Improvecancer treatment efficacyVSAvoidcancer survival rate

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent combines STING agonist therapy with checkpoint inhibitor therapy to create a synergistic treatment regimen. The STING agonist activates innate immunity and induces type-I interferon response, while checkpoint inhibitors block immune checkpoint pathways (PD-1/PD-L1 or CTLA-4), thereby merging two different immunotherapeutic mechanisms to achieve enhanced anti-tumor efficacy and improved cancer survival rates

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The treatment regimen uses a composite therapeutic approach combining two distinct pharmacological agents (STING agonist and checkpoint inhibitor) with different mechanisms of action. This composite therapy strategy allows the treatment to address multiple aspects of tumor immunity simultaneously, overcoming limitations of single-agent therapies and improving overall treatment reliability

Inventive Principle:

Principle #40Composite materials

2Reliability

If targeted cancer therapies (monoclonal antibodies to PD-1, PD-L1, CTLA-4) are used, then immune effect is enhanced, but cancer resistance to treatment may develop

Engineering Contradiction:

Improveimmune effectVSAvoidcancer resistance

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The STING agonist is administered to preemptively activate innate immunity and create a robust immune response before the tumor can develop resistance to checkpoint inhibitors. By establishing strong immune activation through STING pathway engagement, the treatment creates a protective effect that prevents or delays the emergence of treatment-resistant cancer variants

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The combination therapy performs preliminary immune system priming through STING agonist administration, which activates dendritic cells and promotes antigen presentation before checkpoint inhibition is fully engaged. This preliminary action ensures that the immune system is adequately prepared and activated to respond effectively to checkpoint blockade, reducing the likelihood of treatment failure due to resistance

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination therapy enhances cancer treatment efficacy by potentially overcoming resistance and improving patient outcomes, including for advanced and metastatic cancers, through synergistic effects.

Implementation Method 1

STING activation by these natural ligands induces the phosphorylation of TBK1 (TANK binding kinase 1) and IRF3 (Interferon regulatory factor 3), leading to the activation of NFkB and a type-I-interferon (IFN) response, respectively

Methodology Applied

Scientific EffectPhosphorylation:

Implementation Method 2

STING is a transmembrane receptor localized to the ER that recognizes and binds cyclic dinucleotides

Methodology Applied

Scientific EffectBinding:

Implementation Method 3

monoclonal antibodies to PD-1 (e.g., nivolumab/Opdivo®, and) pembrolizumab/Keytruda®), monoclonal antibodies to PD-L1 (e.g., atezolizumab/Tecentriq®, durvalumab/Imfinzi®, and avelumab/Bavencio®), and monoclonal antibodies to CTLA-4 (e.g., ipilimumab/Yervoy®)

Methodology Applied

Scientific EffectBlocking:

Data Source

PatentUS12403154B2Administration of sting agonist and checkpoint inhibitors

Publication Date: 2025.09.02 TAKEDA PHARMA CO LTD

AI summary

The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a STING (stimulator of interferon genes) agonist, such as Compound No. 14, or a pharmaceutically acceptable salt thereof, in combination with one or more checkpoint inhibitors. Suitable checkpoint inhibitors include anti-PD-1 antibodies, anti-PD-L1 antibodies and anti-CTLA-4 antibodies. Also provided are medicaments for use in treating cancer. Compound No. 14 has the structure: